I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Lupus Research Program

Transformative Vision Award

Announcement Type: Initial

Funding Opportunity Number: W81XWH-21-LRP-TVA

Catalog of Federal Domestic Assistance Number: 12.420 Military Medical Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), August 24, 2021
- Application Submission Deadline: 11:59 p.m. ET, September 22, 2021
- End of Application Verification Period: 5:00 p.m. ET, September 27, 2021
- Peer Review: November 2021
- **Programmatic Review:** February 2022

This program announcement must be read in conjunction with the General Application Instructions, version 604. The General Application Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the "Package" tab, clicking "Preview," and then selecting "Download Instructions."

TABLE OF CONTENTS

I.	OVERVIEW OF THE FUNDING OPPORTUNITY	1
II.	DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY	3
	II.A. Program Description	3
	II.A.1. FY21 LRP Focus Areas	3
	II.A.2. Award History	4
	II.B. Award Information	4
	II.C. Eligibility Information	7
	II.C.1. Eligible Applicants	7
	II.C.2. Cost Sharing	7
	II.C.3. Other	8
	II.D. Application and Submission Information	8
	II.D.1. Address to Request Application Package	8
	II.D.2. Content and Form of the Application Submission	8
	II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management (SAM)	. 25
	II.D.4. Submission Dates and Times	. 25
	II.D.5. Funding Restrictions	. 26
	II.D.6. Other Submission Requirements	. 27
	II.E. Application Review Information	. 27
	II.E.1. Criteria	. 27
	II.E.2. Application Review and Selection Process	. 30
	II.E.3. Integrity and Performance Information	. 30
	II.E.4. Anticipated Announcement and Federal Award Dates	. 31
	II.F. Federal Award Administration Information	. 31
	II.F.1. Federal Award Notices	. 31
	II.F.2. Administrative and National Policy Requirements	. 32
	II.F.3. Reporting	. 32
	II.G. Federal Awarding Agency Contacts	. 33
	II.G.1. CDMRP Help Desk	. 33
	II.G.2. Grants.gov Contact Center	. 33
	II.H. Other Information	. 33
	II.H.1. Program Announcement and General Application Instructions Versions	
	II.H.2. Administrative Actions	. 34
	II.H.3. Application Submission Checklist	. 36
AP	PENDIX 1: ACRONYM LIST	. 38

II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

II.A. Program Description

Applications to the Fiscal Year 2021 (FY21) Lupus Research Program (LRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this program announcement is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC). The LRP was initiated in 2017 to provide support for research of exceptional scientific merit leading to a cure for lupus. Appropriations for the LRP from FY17 through FY20 totaled \$25 million (M). The FY21 appropriation is \$10M.

The LRP's mission is to fund research to understand, prevent, and diagnose lupus and to improve treatments and quality of life for patients, including Service Members, Veterans, and beneficiaries.

The LRP's vision is to cure lupus through partnership of scientists, clinicians, and consumers.

The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.

II.A.1. FY21 LRP Focus Areas

To be considered for funding, applications for the FY21 Transformative Vision Award (TVA) **are required** to address the following Focus Area:

• Design and implement an intervention either at the individual and/or healthcare system level to improve the quality of life for individuals living with lupus. Example interventions include, but are not limited to, access to healthcare resources, outcomes research, symptom and disease control, comparative effectiveness research, and issues and challenges that, when addressed, make day-to-day living with lupus easier and life more fulfilling.

Lupus is a complex disease that impacts multiple facets of an individual's life. Because of this, the LRP retains a broad research scope to ensure funding opportunities exist for any promising avenues of research with the potential to lead toward improvements in treatments, patient quality of life, or lessening the severity of symptoms. The LRP welcomes applicants new to the field of lupus research with novel and innovative ideas or technologies for interventions that have the potential to make a significant impact in the lives of individuals with lupus.

II.A.2. Award History

The LRP Transformative Vision Award mechanism was first offered in FY20. Since then, five Transformative Vision Award applications have been received, and one has been recommended for funding.

II.B. Award Information

The TVA supports applications that will fulfill an extraordinary vision for dramatically improving the quality of life of persons with lupus using an intervention at the individual and/or healthcare system level. This award requires a plan that will test and achieve the vision through the translation of research ideas which, when addressed, will result in a near-term impact on the quality of life of persons living with lupus. Applications may address various quality-of-life issues in lupus patients of any age, including but not limited to those with disproportionate health burdens. *Preliminary data are required. Human subject research and clinical trials are allowed under this program announcement.*

The following are important aspects of the Transformative Vision Award:

- **Impact:** The proposed research, if successful, should have a major impact on the quality of life of lupus patients. Applications should clearly and explicitly describe the potential impact(s) of the proposed study for individuals living with lupus and to convey its level of significance. The TVA supports high-risk, high-reward studies that have an intervention with the potential to make a significant, near-term impact on the quality of life of lupus patients.
- **Research Strategy:** The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of lupus. Experimental strategies may be novel or may be based on strong rationale derived from a literature review.
- Focus Areas: The proposed research must address the FY21 LRP Focus Area for the TVA.
- **Research Team:** The research team's background should be appropriate with respect to its ability to successfully complete the proposed work.
- **Consumer Advocate:** Applications are required to include consumer advocate involvement. The research team *must* include one or more consumer advocate(s), who will be integral throughout the planning and implementation of the research project. Consumer advocates should be involved in the development of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. As lay representatives, the consumer advocates must be individuals who have been diagnosed with lupus or a caregiver, and they should be active in a lupus advocacy organization. Their role in the project should be independent of their employment, and they cannot be employees of any of the organizations participating in the application. Their role should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, lupus. The consumer

advocate(s) should have a high level of knowledge of current lupus issues and the appropriate background or training in lupus research to contribute to the project.

• **Budget:** The proposed budget should be appropriate for the proposed research and within the limitations of this program announcement.

Animal research is not allowed under this program announcement.

The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.

Partnering Principal Investigator (PI) Option:

The Transformative Vision Award encourages applications that include meaningful and productive collaborations between investigators. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as a Partnering PI(s), with **a maximum of two** Partnering PIs. All PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. If recommended for funding, each PI will be named to an individual award within the recipient organization. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.

The types of awards made under the program announcement will be assistance agreements. An assistance agreement is appropriate when the federal government transfers a "thing of value" to a "state, local government," or "other recipient" to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the Department of Defense (DOD) during project performance is the key factor in determining whether to award a grant or cooperative agreement. If "no substantial involvement" on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.

The anticipated total costs budgeted for the entire period of performance for an FY21 LRP Transformative Vision Award will not exceed **\$2,500,000**. Refer to <u>Section II.D.5, Funding</u> <u>Restrictions</u>, for detailed funding information.

Awards will be made no later than September 30, 2022. For additional information refer to <u>Section II.F.1, Federal Award Notices</u>.

The CDMRP expects to allot approximately \$2.5M to fund approximately one Transformative Vision Award application. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received,

the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY21 funding opportunity will be funded with FY21 funds, which will expire for use on September 30, 2027.

Research Involving Human Anatomical Substances, Human Subjects, or Human

Cadavers: All DOD-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the USAMRDC Office of Research Protections (ORP), Human Research Protection Office (HRPO), prior to research implementation. This administrative review requirement is in addition to the local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of submission is *not* required. *Allow a minimum of 2 to 3 months for HRPO regulatory review and approval processes*. Refer to the General Application Instructions, Appendix 1, and the Human Research Protections Office Resources and Overview document available on the electronic Biomedical Research Application Portal (eBRAP) "Funding Opportunities & Forms" web page (<u>https://ebrap.org/eBRAP/public/Program.htm</u>) for additional information.

If the proposed research is cooperative (i.e., involving more than one institution), a written plan for single IRB review arrangements must be provided at the time of application submission or award negotiation. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements.

A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

Clinical research is defined as: (1) patient-oriented research. Research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. Patient-oriented research includes: (a) mechanisms of human disease, (b) therapeutic interventions, (c) clinical trials, and (d) development of new technologies; (2) epidemiologic and behavioral studies; and (3) outcomes research and health services research. *Note:* Studies that meet the requirements for Institutional Review Board (IRB) Exemption 4 are not considered CDMRP-defined clinical research. IRB Exemption 4 refers to research involving the collection or study of existing de-identified specimens or data, if these sources are publicly available.

Use of DOD or Department of Veterans Affairs (VA) Resources: If the proposed research involves access to active-duty military patient populations and/or DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to <u>Section II.D.2.b.ii,</u> <u>Full Application Submission Components</u>, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.

II.C. Eligibility Information

II.C.1. Eligible Applicants

II.C.1.a. Organization: All organizations, including foreign organizations, foreign public entities, and international organizations, are eligible to apply.

Government Agencies Within the United States: Local, state, and federal government agencies are eligible to the extent that applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their applications do not overlap with their internal programs.

As applications for this program announcement may be submitted by extramural and intramural organizations, these terms are defined below.

Extramural Organization: An eligible non-DOD organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, federal government organization other than the DOD, and research institutes.

Intramural DOD Organization: A DOD laboratory, DOD military treatment facility, and/or DOD activity embedded within a civilian medical center. *Intramural Submission: Application submitted by a DOD organization for an intramural investigator working within a DOD laboratory or military treatment facility or in a DOD activity embedded within a civilian medical center.*

USAMRAA makes awards to eligible organizations, not to individuals.

II.C.1.b. Principal Investigator

Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible to be named by the applicant organization as the PI.

Each investigator may be named on only one FY21 LRP Transformative Vision Award application as either the Initiating PI or a Partnering PI.

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.

The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at <u>https://orcid.org/</u>.

II.C.2. Cost Sharing

Cost sharing/matching is not an eligibility requirement.

II.C.3. Other

Organizations must be able to access **.gov** and **.mil** websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 3.

Refer to <u>Section II.H.2</u>, <u>Administrative Actions</u>, for a list of administrative actions that may be taken if a pre-application or application does not meet the administrative, eligibility, or ethical requirements defined in this program announcement.

II.D. Application and Submission Information

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

Extramural Submission:

- Pre-application content and forms must be accessed and submitted at <u>eBRAP.org</u>.
- Full application packages must be accessed and submitted at Grants.gov.

Intramural DOD Submission:

- Pre-application content and forms must be accessed and submitted at <u>eBRAP.org</u>.
- Full application packages must be accessed and submitted at <u>eBRAP.org</u>.

Note: Applications from an intramural DOD organization or from an extramural federal government organization may be submitted to Grants.gov through a research foundation.

II.D.1. Address to Request Application Package

eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance.

Contact information for the CDMRP Help Desk and the Grants.gov Contact Center can be found in <u>Section II.G</u>, Federal Awarding Agency Contacts.

II.D.2. Content and Form of the Application Submission

Submission is a two-step process requiring both *pre-application* (eBRAP.org) and *full application* (eBRAP.org or Grants.gov) as indicated below. The submission process should be started early to avoid missing deadlines. There are no grace periods. Full application

submission guidelines differ for extramural (Grants.gov) and intramural (eBRAP.org) organizations (refer to <u>Table 1, Full Application Guidelines</u>).

The application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the CDMRP Help Desk at <u>help@eBRAP.org</u> or 301-682-5507 prior to the application submission deadline.

Partnering PI Option:

The Initiating PI must complete the pre-application submission process and submit the contact information for each Partnering PI. Each Partnering PI will then be notified of the preapplication submission separately by email. *Each Partnering PI must follow the link in the notification email in order to associate their full application package with that of the Initiating PI. After following the link, each Partnering PI must verify their contact information, organization, and designation as an extramural or intramural submission within eBRAP.* If not previously registered, the Partnering PI(s) must register in eBRAP. A new pre-application based on this research project should not be initiated by the Partnering PI(s). Applicants are urged to complete these steps as soon as possible. If they are not completed, the Partnering PI(s) will not be able to view and modify their application during the verification period in eBRAP. If these steps are not completed, an intramural partner will not be able to submit the Partnering PI's required full application package components to eBRAP.

II.D.2.a. Step 1: Pre-Application Submission Content

During the pre-application process, eBRAP assigns each submission a unique log number. This unique eBRAP log number is required during the full application submission process.

To begin the pre-application process, first select whether the submitting organization is extramural or intramural, then confirm your selection or cancel. **Incorrect selection of extramural or intramural submission type will delay processing.**

If an error has been made in the selection of extramural versus intramural and the pre-application submission deadline has passed, the PI or Business Official must contact the CDMRP Help Desk at <u>help@eBRAP.org</u> or 301-682-5507 to request a change in designation.

All pre-application components must be submitted by the PI through eBRAP (<u>https://eBRAP.org/</u>).

The applicant organization and associated PI identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the applicant must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

PIs with an ORCID identifier should enter that information in the appropriate field in the "My Profile" tab in the "Account Information" section of eBRAP.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B, for additional information on pre-application submission):

• Tab 1 – Application Information

Submission of application information includes assignment of primary and secondary research classification codes, which may be found at <u>https://ebrap.org/eBRAP/public/Program.htm</u>. Applicants are strongly encouraged to review and confirm the codes prior to making their selection.

• Tab 2 – Application Contacts

Enter contact information for the PI. Enter the organization's Business Official responsible for sponsored program administration (the "person to be contacted on matters involving this application" in Block 5 of the Grants.gov SF424 Research & Related Form). The Business Official must be either selected from the eBRAP list or invited in order for the pre-application to be submitted.

Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 Research & Related Form), and click on "Add Organizations to this Pre-application." The organization(s) must be either selected from the eBRAP drop-down list or invited in order for the pre-application to be submitted.

It is recommended that applicants identify an Alternate Submitter in the event that assistance with pre-application submission is needed.

• Tab 3 – Collaborators and Key Personnel

Enter the name, organization, and role of all collaborators and key personnel associated with the application.

Consumer Advocate: At least one lupus consumer advocate must also be named; failure to do so may result in administrative withdrawal of the application. The lupus consumer advocate's role in the project should be independent of their employment and they cannot be an employee of any of the organizations participating in the application.

Partnering PI Option: The Initiating PI must enter the contact information for the Partnering PI(s) in the Partnering PI section.

<u>FY21 LRP Programmatic Panel members</u> should not be involved in any pre-application or application. For questions related to panel members and pre-applications or applications, refer to <u>Section II.H.2.c</u>, <u>Withdrawal</u>, or contact the CDMRP Help Desk at <u>help@eBRAP.org</u> or 301-682-5507.

• Tab 4 – Conflicts of Interest

List all individuals other than collaborators and key personnel who may have a conflict of interest in the review of the application (including those with whom the PI has a personal or professional relationship).

• Tab 5 – Pre-Application Files

Letter of Intent (LOI) (one-page limit): Provide a brief description of the research to be conducted. Describe how the research is aligned with the FY21 LRP TVA Focus Area identified in Section II.A.1, LRP Focus Area. LOIs are used for program planning purposes only (e.g., reviewer recruitment) and will not be reviewed during either the peer or programmatic review sessions. An invitation to submit is *not* required.

• Tab 6 – Submit Pre-Application

This tab must be completed for the pre-application to be accepted and processed.

II.D.2.b. Step 2: Full Application Submission Content

The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.

Each application submission must include the completed full application package for this program announcement. The full application package is submitted by the Authorized Organizational Representative through Grants.gov (<u>https://www.grants.gov/</u>) for extramural organizations or through eBRAP (<u>https://ebrap.org/</u>) for intramural organizations. See Table 1 below for more specific guidelines.

II.D.2.b.i. Full Application Guidelines

Extramural organizations must submit full applications through Grants.gov. Applicants must create a Grants.gov Workspace for submission, which allows the application components to be completed online and routed through the applicant organization for review prior to submission. Applicants may choose to download and save individual PDF forms rather than filling out webforms in Workspace. A compatible version of Adobe Reader **must** be used to view, complete, and submit an application package consisting of PDF forms. If more than one person is entering text into an application package, the *same version* of Adobe Reader software should be used by each person. Check the version number of the Adobe software on each user's computer to make sure the versions match. Using different versions of Adobe Reader may cause submission and/or save errors – even if each version is individually compatible with Grants.gov. Refer to the General Application Instructions, Section III, and the "Apply For Grants" page of Grants.gov (https://www.grants.gov/web/grants/applicants/apply-for-grants.html) for further information about the Grants.gov Workspace submission process. Submissions of extramural applications through eBRAP may be withdrawn.

Do not password protect any files of the application package, including the Project Narrative.

Extramural Submissions	Intramural DOD Submissions		
Application Package Location			
Download application package components for W81XWH-21-LRP-TVA from Grants.gov (<u>https://www.grants.gov</u>) and create a Grants.gov Workspace. Workspace allows online completion of the application components and routing of the application package through the applicant organization for review prior to submission.	Download application package components for W81XWH-21-LRP-TVA from eBRAP (<u>https://ebrap.org</u>).		
Full Application Pa	Full Application Package Components		
SF424 Research & Related Application for Federal Assistance Form: Refer to the General Application Instructions, Section III.A.1, for detailed information.	 Tab 1 – Summary: Provide a summary of the application information. Tab 2 – Application Contacts: This tab will be pre-populated by eBRAP; add Authorized Organizational Representative. 		
 Descriptions of each required file can be found under Full Application Submission Components: <u>Attachments</u> <u>Research & Related Personal Data</u> <u>Research & Related Senior/Key Person</u> <u>Profile (Expanded)</u> <u>Research & Related Budget</u> <u>Project/Performance Site Location(s) Form</u> <u>Research & Related Subaward Budget</u> <u>Attachment(s) Form</u> 	 Tab 3 – Full Application Files: Upload files under each Application Component in eBRAP. Descriptions of each required file can be found under Full Application Submission Components: <u>Attachments</u> <u>Key Personnel</u> <u>Budget</u> <u>Performance Sites</u> Tab 4 – Application and Budget Data: Review and edit proposed project start date, proposed end date, and budget data pre-populated from the Budget Form. 		

Table 1. Full Application Submission Guidelines

Extramural Submissions	Intramural DOD Submissions		
Application Package Submission			
Create a Grants.gov Workspace. Add participants (investigators and Business Officials) to Workspace, complete all required forms, and check for errors before submission. Submit a Grants.gov Workspace Package. An application may be submitted through Workspace by clicking the "Sign and Submit" button on the "Manage Workspace" page, under the "Forms" tab. Grants.gov recommends submission of the application package at least 24-48 hours prior to the close date to allow time to correct any potential technical issues that may disrupt the application submission. <i>Note:</i> If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or the budget needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a "Changed/Corrected Application" with the previous Grants.gov Tracking ID <i>prior to</i> the application submission deadline. <i>Do not password protect any files of the</i> <i>application package, including the Project</i> <i>Narrative.</i>	Submit package components to eBRAP (https://ebrap.org). Tab 5 – Submit/Request Approval Full Application: After all components are uploaded and prior to the full application submission deadline, enter your password in the space provided next to "Enter Your Password Here" and press the "Submit Full Application" button. eBRAP will notify your Resource Manager/ Comptroller/Task Area Manager or equivalent Business Official by email. <i>Do not password</i> <i>protect any files of the application package,</i> <i>including the Project Narrative.</i>		
Application Ver	ification Period		
The full application package submitted to Grants.gov may be viewed and modified in eBRAP	After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/ Task Area Manager or equivalent Business Official and PI(s) will receive email notification of this status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package may be modified <i>with the exception of</i> <i>the Project Narrative and Research & Related</i> <i>Budget Form</i> . Your Resource Manager/ Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve prior to the application verification deadline.		

Extramural Submissions	Intramural DOD Submissions	
Further Information		
Tracking a Grants.gov Workspace Package. After successfully submitting a Workspace package, a Grants.gov Tracking Number is automatically assigned to the package. The number will be listed on the "Confirmation" page that is generated after submission.	Refer to the General Application Instructions, Section IV, for further information regarding eBRAP requirements.	
Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.		

Partnering PI Option: The CDMRP requires separate full application package submissions for the Initiating PI and each Partnering PI, even if the PIs are located within the same organization. Initiating and Partnering PIs will each be assigned a unique eBRAP log number. Each full application package must be submitted using the unique eBRAP log number. *Note: All associated applications (Initiating PI's and each Partnering PI's) must be submitted by the full application submission deadline.*

The full application package must be submitted using the unique eBRAP log number to avoid delays in application processing.

II.D.2.b.ii. Full Application Submission Components

• Extramural Applications Only

SF424 Research & Related Application for Federal Assistance Form: Refer to the General Application Instructions, Section III.A.1, for detailed information.

• Extramural and Intramural Applications

Attachments:

Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 4.

For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or have incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB, and the file size for the entire full application package may not exceed 200 MB.

• Attachment 1: Project Narrative (20-page limit): Upload as

"ProjectNarrative.pdf". The page limit of the Project Narrative applies to text and nontext elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

- Background/Rationale: Briefly describe the ideas and reasoning on which the proposed work is based. Throughout the Project Narrative, clearly convey how the proposed research if successful will have a major impact by transforming the quality of life of lupus patients. Demonstrate logical reasoning and provide a sound scientific rationale for the proposed project as established through a critical review and analysis of published literature. Inclusion of preliminary data is required and the preliminary data should support the feasibility of the work proposed. If proposing translational research, it is important to describe the studies showing proof of concept and clinical relevance.
- Hypothesis(es) or Objective(s): State the hypothesis(es) to be tested or the objective(s) to be reached.
- Specific Aims: Concisely explain the project's specific aims proposed.
- Research Strategy:
 - Explain how the hypothesis(es) or objective(s), aims, experimental design, methods, statistical analysis plan, and analyses are developed and integrated into the project.
 - Explain how the experimental design and methodology are appropriate to address the stated objectives.
 - Address how the application acknowledges potential problems and addresses alternative approaches.
 - Provide sufficient evidence to support availability of and access to the populations/samples required for the study, and a sufficient plan for acquiring the necessary research resources for the proposed research project (if applicable).
 - For applications proposing accrual of a new cohort of human subjects, describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex/gender, racial, and ethnic group, and an accompanying rationale for the selection of subjects.
 - If the methodology is new or unusual, provide sufficient details for evaluation.

- For Applications proposing a clinical trial:

- Describe how the type of clinical trial (e.g., prospective, randomized, controlled) proposed is appropriate to meet the project's objectives.
- Explain how the clinical trial is designed with appropriate study variables, controls, and endpoints.
- Describe the availability of, and access to, the appropriate patient population(s), as well as the ability to accrue a sufficient number of subjects.
- Explain the plan for applying for and obtaining Investigational New Drug/ Investigational Device Exemption (IND/IDE) status (or other U.S. Food and Drug Administration [FDA] approvals), if applicable.
- Describe potential challenges and alternative strategies.

– Personnel:

- Explain how the research team's background is appropriate with respect to its ability to perform the proposed work, including evidence of sufficient clinical and/or statistical expertise (if applicable).
- Explain how the levels of effort are appropriate for successful completion of the proposed work.
- Provide the name of the consumer advocate and their affiliation with a lupus advocacy organization(s). Describe the integral roles that the consumer advocate will play in the planning, design, implementation, and evaluation of the research.

In addition, if applying under the Partnering PI Option,

- Describe how the partners bring different strengths to the application.
- Describe how their combined expertise in the collaboration will better address the research question.
- Explain why the work should be done together rather than through separate efforts.
- Attachment 2: Supporting Documentation: Combine and upload as a single file named "Support.pdf". Start each document on a new page. If documents are scanned to PDF, the lowest resolution (100 to 150 dpi) should be used. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

- References Cited: List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).
- List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.
- Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present government award under which the facilities or equipment items are now accountable. There is no form for this information.
- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- Consumer Advocate Letter of Commitment: Provide a letter signed by the lupus consumer advocate confirming their role and commitment to participate on the research team.
- Letters of Organizational Support: Provide a letter (or letters, if applicable) signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the program announcement, such as those from members of Congress, do not impact application review or funding decisions.
- Letters of Collaboration (if applicable): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work. If an investigator at an intramural organization is named as a collaborator on an application submitted through an extramural organization, the application must include a letter from the collaborator's Commander or Commanding Officer at the intramural organization that authorizes the collaborator's involvement.
- Inclusion Enrollment Plan: For applications proposing accrual of a new cohort of human subjects, provide an anticipated enrollment table(s) for the inclusion of women and minorities appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex/gender, race, and ethnicity. The suggested Inclusion

Enrollment Report format is a one-page fillable PDF form, which can be downloaded from eBRAP at <u>https://ebrap.org/eBRAP/public/Program.htm</u>.

- Intellectual Property: Information can be found in Code of Federal Regulations, Title 2, Part 200.315 (2 CFR 200.315), "Intangible Property."
 - Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.
 - Commercialization Strategy (if applicable): Describe the commercialization plan. The plan should include intellectual property, market size, financial analysis, strengths and weaknesses, barriers to the market, competitors, and management team. Discuss the significance of this development effort, when it can be anticipated, and the potential commercial use for the technology being developed.
- Data and Research Resources Sharing Plan: Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Application Instructions, Appendix 2, Section K, for more information about the CDMRP expectations for making data and research resources publicly available.
- Use of DOD Resources (if applicable): Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to active-duty military populations and/or DOD resources or databases.
- Use of VA Resources (if applicable): Provide a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief, confirming access to VA patients, resources, and/or VA research space. For VA PIs, if the VA non-profit corporation is not identified as the applicant institution for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.
- Attachment 3: Technical Abstract (one-page limit): Upload as "TechAbs.pdf". The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. *Do not include proprietary or confidential information*. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Technical abstracts should be written using the outline below:

- **Background/Rationale:** Present the ideas and reasoning behind the proposed project.
- Hypothesis(es) or Objective(s): State the hypothesis(es) to be tested or the objective(s) to be reached.

- **Specific Aims:** State the specific aims of the study.
- **Research Strategy:** Briefly describe the research strategy to include methodology, statistical analysis plan, and appropriate controls.
- Impact: Summarize the near-term impact of the proposed research, if successful, on the quality of life of lupus patients of all ages and those with disproportionate health burdens.
- Attachment 4: Lay Abstract (one-page limit): Upload as "LayAbs.pdf". The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. *Do not include proprietary or confidential information*. *Do not duplicate the technical abstract*. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Lay abstracts should be written using the outline below. Do not duplicate the technical abstract. Minimize use of acronyms and abbreviations, where appropriate. The lay abstract is an important component of the application review process because it addresses issues of particular interest to the consumer community.

- Clearly describe, in a manner readily understood by readers without a background in science or medicine, the rationale, objective, and aims of the application.
- Describe the relationship of the proposed work to the specific Focus Area of this program announcement.
- Describe the ultimate applicability of the research.
 - What types of patients will it help and how will it help them?
 - What are the potential clinical applications, benefits, and risks?
 - What is the projected time it may take to achieve a patient-related outcome?
 - What is the likely near-term impact of the proposed research, if successful, on the quality of life of lupus patients of all ages and those with disproportionate health burdens?
- Attachment 5: Statement of Work (three-page limit): Upload as "SOW.pdf". The suggested SOW format and examples specific to different types of research projects are available on the eBRAP "Funding Opportunities & Forms" web page (<u>https://ebrap.org/eBRAP/public/Program.htm</u>). Recommended strategies for assembling the SOW can be found at <u>https://ebrap.org/eBRAP/public/Program.htm</u>.

For the Transformative Vision Award, refer to either the "Suggested SOW Strategy Clinical Research" or "Suggested SOW Strategy Generic Research", whichever format

is most appropriate for the proposed effort, and use the blank SOW format titled "Suggested SOW Format". The SOW must be in PDF format prior to attaching.

The SOW should include a list of major tasks that support the proposed specific aims, followed by a series of subtasks outlined related to the major tasks and milestones within the period of performance. The SOW should describe only the work for which funding is being requested by this application and, as applicable, should also:

- Include the name(s) of the key personnel and contact information for each study site/ subaward site.
- Indicate the number (and type, if applicable) of research subjects (human) and/or human anatomical samples projected or required for each task and at each site. Refer to the General Application Instructions, Appendix 1, for additional information regarding regulatory requirements.
- For studies with prospective accrual of human subjects, indicate quarterly enrollment targets.
- Identify cell line(s) and commercial or organizational source(s) to be used.
- If applicable, indicate timelines required for regulatory approvals relevant to human subjects research (e.g., IND and IDE applications) by the FDA or other government agency.

Partnering PI Option: Each PI must submit an identical copy of a jointly created SOW. The contributions of the Initiating PI and each Partnering PI should be noted for each task.

• Attachment 6: Impact Statement (two-page limit): Upload as "Impact.pdf".

- Clearly describe, in a manner readily understood by readers without a background in science or medicine, to what extent the proposed research will have a major near-term impact on the quality of life of lupus patients.
- Describe how the proposed research moves beyond an incremental advancement.
- Attachment 7: Representations, if applicable (extramural submissions only): Upload as "RequiredReps.pdf". All extramural applicants must complete and submit the Required Representations template available on eBRAP (<u>https://ebrap.org/eBRAP/ public/Program.htm</u>). For more information, see the General Application Instructions, Appendix 5, Section B, Representations.
- Attachment 8: Suggested Collaborating DOD Military Facility Budget Format, if applicable: Upload as "MFBudget.pdf". If a military facility (Military Health System facility, research laboratory, medical treatment facility, dental treatment facility, or a DOD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete a separate budget, using "Suggested Collaborating

DOD Military Facility Budget Format", available for download on the eBRAP "Funding Opportunities & Forms" web page <u>https://ebrap.org/eBRAP/public/Program.htm</u>), including a budget justification, for each military facility as instructed. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Application Instructions, Section III.A.8, for detailed information.

• Extramural and Intramural Applications

To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC 1681(a) et seq.), the DOD is collecting certain demographic and career information to be able to assess the success rates of women who are proposed for key roles in applications in science, technology, engineering, and/or mathematics (STEM) disciplines. To enable this assessment, each application must include the following forms completed as indicated.

Research & Related Personal Data: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.3, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.2, for detailed information.

Research & Related Senior/Key Person Profile (Expanded): For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3, for detailed information.

- PI Biographical Sketch (five-page limit): Upload as "Biosketch_LastName.pdf". The suggested biographical sketch format is available on the "Funding Opportunities & Forms" web page (<u>https://ebrap.org/eBRAP/public/Program.htm</u>) in eBRAP. The National Institutes of Health (NIH) Biographical Sketch may also be used. All biographical sketches should be submitted in uneditable PDF format.
- PI Previous/Current/Pending Support (no page limit): Upload as "Support_LastName.pdf".
 - For extramural submissions, refer to the General Application Instructions, Section III.A.4 for detailed information.
 - For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.
- Key Personnel Biographical Sketches (five-page limit each): Upload as "Biosketch_LastName.pdf".
 - Include biographical sketches for team members, including consumer advocates.

• Key Personnel Previous/Current/Pending Support (no page limit): Upload as "Support_LastName.pdf".

Research & Related Budget: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.5, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.4, for detailed information.

Budget Justification (no page limit): Upload as "BudgetJustification.pdf". The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

Partnering PI Option: Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Initiating PI should not include budget information for Partnering PI(s) even if they are located within the same organization. Refer to Section II.D.5, Funding Restrictions, for detailed information.

Project/Performance Site Location(s) Form: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.6, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.5, for detailed information.

• Extramural Applications Only

Research & Related Subaward Budget Attachment(s) Form (if applicable): Refer to the General Application Instructions, Section III.A.7, for detailed information.

- **Extramural Subaward:** Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.7, for detailed information.) Verify subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.
- Intramural DOD Collaborator(s): Complete the "Suggested Collaborating DOD Military Facility Budget Format" and upload to Grants.gov attachment form as <u>Attachment 8</u>. (Refer to the General Application Instructions, Section IV.A.4, for detailed information.) Each Intramural DOD Collaborator should include costs per year on the Grants.gov Research & Related Budget Form under subaward costs.

Suggested DOD Military Budget Format: A military facility collaborating in the performance of the project (but not participating as a Partnering PI) should be treated as a subaward for budget purposes. *Note:* Applicants should complete a separate military budget using "Suggested Collaborating DOD Military Facility Budget Format" (available for download on the eBRAP "Funding Opportunities & Forms" web page [https://ebrap.org/eBRAP/public/Program.htm]) (Attachment 8) to show all direct and indirect costs. The costs per year should be included on the Grants.gov Research & Related

Budget Form under subaward costs. Refer to the General Application Instructions, Section III.A.8, for detailed information.

Application Components for each Partnering PI

Each Partnering PI must follow the link in the email from eBRAP and, if not registered in eBRAP, complete the registration process prior to the application submission deadline in order to associate their full application package with that of the Initiating PI.

For each Partnering PI, the Initiating PI must identify if each Partnering PI will be named on an extramural or intramural application (in accordance with the guidelines in <u>Section II.C.1.a</u>, <u>Organization</u>) and the appropriate mode of submission (Grants.gov for extramural and eBRAP for intramural). Each Partnering PI must verify their contact information and mode of submission within eBRAP to ensure proper submission of their application.

The application submission process for each Partnering PI uses an abbreviated full application package that includes:

• Extramural and Intramural Applications

Attachments:

- Attachment 5: Statement of Work (three-page limit): Upload as "SOW.pdf". Refer to the General Application Instructions, Section III.A.2, for detailed information on completing the SOW. Each PI must submit an identical copy of a jointly created SOW. The contributions of the Initiating PI and each Partnering PI should be noted for each task.
- Attachment 7: Representations (extramural submissions only): Upload as "RequiredReps.pdf". All extramural applicants must complete and submit the Required Representations template available on eBRAP (<u>https://ebrap.org/eBRAP/</u> <u>public/Program.htm</u>). For more information, see the General Application Instructions, Appendix 5, Section B, Representations.
- Attachment 8: Suggested Collaborating DOD Military Facility Budget Format: Upload as "MFBudget.pdf". Refer to the General Application Instructions, Section IV.A.4, for detailed information. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs.

Research & Related Personal Data: For extramural submissions (via Grants.gov) refer to the General Application Instructions, Section III.A.3, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.2, for detailed information.

Research & Related Senior/Key Person Profile (Expanded): For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3, for detailed information.

- PI Biographical Sketch (five-page limit): Upload as "Biosketch_LastName.pdf". The suggested biographical sketch format is available on the "Funding Opportunities & Forms" web page (<u>https://ebrap.org/eBRAP/public/Program.htm</u>) in eBRAP. The NIH Biographical Sketch may also be used. All biographical sketches should be submitted in the PDF format that is not editable.
- PI Previous/Current/Pending Support (no page limit): Upload as "Support_LastName.pdf".
 - For extramural submissions, refer to the General Application Instructions, Section III.A.4 for detailed information.
 - For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.
- Key Personnel Biographical Sketches (five-page limit each): Upload as "Biosketch_LastName.pdf".
- Key Personnel Previous/Current/Pending Support (no page limit): Upload as "Support_LastName.pdf".

Research & Related Budget: For extramural submissions, refer to the General Application Instructions, Section III.A.5, and for intramural submissions, refer to the General Application Instructions, Section IV.A.4, for detailed information.

Budget Justification (no page limit): Upload as "BudgetJustification.pdf".

Initiating and Partnering PIs must each submit a budget and justification specific to their own portion of the efforts as part of their separate Grants.gov or eBRAP application packages. The Research & Related Budget for each Partnering PI should not include budget information for the Initiating PI, even if they are located within the same organization. Refer to <u>Section II.D.5, Funding Restrictions</u>, for detailed information.

Project/Performance Site Location(s) Form: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.6, and for intramural submissions (via eBRAP), refer to General Application Instructions, Section IV.A.5, for detailed information.

• Extramural Applications Only

Research & Related Subaward Budget Attachment(s) Form:

- **Extramural Subaward:** Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.7, for detailed information.)
- Intramural DOD Collaborator(s): Complete a separate DOD military budget, using Suggested Collaborating DOD Military Facility Budget Format (available for download

on the eBRAP "Funding Opportunities & Forms" web page [https://ebrap.org/eBRAP/public/Program.htm]), and upload to Grants.gov attachment form as <u>Attachment 8</u>. (Refer to the General Application Instructions, Section III.A.8, for detailed information.)

II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management (SAM)

Applicant organizations and all sub-recipient organizations must have a DUNS number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an "Active" status to submit applications through the Grants.gov portal. Verify the status of the applicant organization's Entity registration in SAM well in advance of the application submission deadline. Allow several weeks to complete the entire SAM registration process. If an applicant has not fully complied with the requirements at the time the federal awarding agency is ready to make a federal award, the federal awarding agency may determine that the applicant is not qualified to receive a federal award and use that determination as a basis for making a federal award to another applicant. Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

Announcement of Transition to SAM-Generated Unique Entity Identifier (UEI): Through April 2022, a transition from DUNS to the SAM-generated UEI will occur. Refer to the General Application Instructions, Section III.1, DUNS Number, for more information on the transition and timing.

II.D.4. Submission Dates and Times

All submission dates and times are indicated in <u>Section I, Overview of the Funding Opportunity</u>. Pre-application and application submissions are required. The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

Applicant Verification of Full Application Submission in eBRAP

For Both Extramural and Intramural Applicants: eBRAP allows an organization's representatives and PIs to view and modify the full application submissions associated with them. Following retrieval and processing of the full application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the full application submission. eBRAP will validate full application files against the specific program announcement requirements, and discrepancies will be noted in an email to the PI and in the "Full Application Files" tab in eBRAP. eBRAP does not confirm the accuracy of file content. Application viewing, modification, and verification in eBRAP are strongly recommended, but not required. It is the applicant's responsibility to review all application components and ensure proper ordering as specified in the program announcement. *If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the application submission deadline. The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.* Other application components may be changed until the end

of the application verification period. Verify that subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period. After the end of the application verification period, the full application cannot be modified.

Extramural Submission: The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package, *with the exception of the Project Narrative and Budget Form*, may be modified.

Intramural DOD Submission: After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI(s) will receive email notification of the status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package, *with the exception of the Project Narrative and Budget Form*, may be modified. The Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve the application package prior to the application verification deadline.

For All Submissions: Verify that subaward budget(s) with budget justification are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

II.D.5. Funding Restrictions

The maximum period of performance is 4 years.

The anticipated total costs budgeted for the entire period of performance will not exceed **\$2,500,000**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. No budget will be approved by the government exceeding **\$2,500,000** total costs or using an indirect cost rate exceeding the organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **4** years.

Partnering PI Option: The anticipated combined total costs budgeted for the entire period of performance for the Initiating PI's and each Partnering PI's applications will not exceed **\$2,500,000**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate. The combined budgeted total costs approved by the government will not exceed **\$2,500,000** or use an indirect cost rate exceeding each organization's negotiated rate.

A separate award will be made to each PI's organization.

For this award mechanism, direct costs may be requested for travel including:

- Travel in support of multidisciplinary collaborations.
- Costs to travel to one scientific/technical meeting per year in addition to present project information or disseminate project results from the FY21 LRP TVA.

Must not be requested for:

• Animal research

For extramural awards with an intragovernmental component, direct transfer of funds from an extramural award recipient to a DOD or other federal agency is not allowed except under very limited circumstances. Funding to intramural DOD and other federal agencies will be managed through a direct funds transfer. Intramural applicants are responsible for coordinating through their agency's procedures the use of contractual or assistance funding awards or other appropriate agreements to support extramural collaborators.

Refer to the General Application Instructions, Section III.A.5, for budget regulations and instructions for the Research & Related Budget. *For federal agencies or organizations collaborating with federal agencies, budget restrictions apply as are noted in the General Application Instructions, Section III.A.5.*

II.D.6. Other Submission Requirements

Refer to the General Application Instructions, Appendix 4, for detailed formatting guidelines.

II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

To determine technical merit, all applications will be evaluated according to the following **scored criteria**, which are of equal importance:

- Impact:
 - To what extent the proposed research will have a major near-term impact on the quality of life of lupus patients.
 - To what extent the proposed research moves beyond an incremental advancement.

• Research Strategy:

• To what degree the proposed research is supported by a sound scientific rationale as demonstrated by a critical review and analysis of published literature, and preliminary data.

- How well the hypotheses or objectives, aims, experimental design, methods, statistical analysis plan, and analyses are developed and integrated into the project.
- To what degree the experimental design and methodology are appropriate to address the stated objectives.
- How well the application acknowledges potential problems and addresses alternative approaches.
- Whether the application has provided sufficient evidence to support availability of and access to the populations/samples required for the study, and whether the plan for acquiring the necessary research resources is sufficient for the proposed research project (if applicable).
- For applications proposing prospective accrual of human subjects, the extent to which the strategy for the inclusion of women and minorities and distribution of proposed enrollment are appropriate for the proposed research.

For applications proposing a clinical trial:

- Whether the type of clinical trial (e.g., prospective, randomized, controlled) proposed is appropriate to meet the project's objectives.
- Whether the clinical trial is designed with appropriate study variables, controls, and endpoints.
- How well the application demonstrates the availability of, and access to, the appropriate patient population(s), as well as the ability to accrue a sufficient number of subjects.
- Whether the plan for applying for and obtaining the IND/IDE status (or other FDA approvals) is appropriate, if applicable.
- Whether potential challenges and alternative strategies are appropriately identified.

Personnel:

- To what degree the research team's background is appropriate with respect to its ability to perform the proposed work, including whether there is evidence of sufficient clinical and/or statistical expertise (if applicable).
- Whether the levels of effort are appropriate for successful completion of the proposed work.
- How well the application describes the integral roles that the consumer advocate will play in the planning, design, implementation, and evaluation of the research.

In addition, if applying under the Partnering PI Option:

• How well the partners bring different strengths to the applications.

- How well their combined expertise in the collaboration will better address the research question.
- How well the application explained why the work should be done together rather than through separate efforts.

• Budget

- Whether the **total** maximum costs exceed the allowable total maximum costs as published in the program announcement.
- Whether the budget is appropriate for the proposed research.

In addition, the following **unscored** criteria will also contribute to the overall evaluation of the application:

• Environment

- Whether the scientific environment is appropriate for the proposed research.
- If applicable, to what degree the intellectual and material property plan is appropriate.
- How well the research requirements are supported by the availability of, and access to facilities and resources (including collaborative arrangements).
- Whether the quality and extent of institutional support are appropriate for the proposed research.

• Application Presentation

To what extent the writing, clarity, and presentation of the application components influence the review.

II.E.1.b. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of the peer reviewers
- Relevance to the mission of the DHP and FY21 LRP, as evidenced by the following:
 - Adherence to the intent of the award mechanism
 - Program portfolio composition
 - Relative near-term impact

II.E.2. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC, on behalf of the DHA and the OASD(HA). *The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in <u>Section II.E.1.b,</u> <u>Programmatic Review</u>. Additional information about the two-tier process used by the CDMRP can be found at <u>https://cdmrp.army.mil/about/2tierRevProcess</u>. An information paper describing the funding recommendations and review process for the award mechanisms for the LRP will be provided to the PI(s) and posted on the CDMRP website.*

All CDMRP review processes are conducted confidentially to maintain the integrity of the meritbased selection process. Panel members sign a statement declaring that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization's application. Violations by panel members or applicants that compromise the confidentiality of the review and approval process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.

II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.88, over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the Federal Awardee Performance and Integrity Information System (FAPIIS).

An applicant organization may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about the organization that a federal awarding agency previously entered and is currently available in FAPIIS.

The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics, and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

II.E.4. Anticipated Announcement and Federal Award Dates

All application review dates and times are indicated in <u>Section I, Overview of the Funding</u> <u>Opportunity</u>.

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Awards supported with FY21 funds are anticipated to be made no later than September 30, 2022. Refer to the General Application Instructions, Appendix 2, for additional award administration information.

After email notification of application review results through eBRAP, and if selected for funding, a representative from USAMRAA will contact the Business Official authorized to negotiate on behalf of the PI's organization.

Pre-Award Costs: An institution of higher education, hospital, or other non-profit organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award. Refer to the General Application Instructions, Section III.A.5.

Only an appointed USAMRAA Grants Officer may obligate the government to the expenditure of funds. No commitment on the part of the government should be inferred from discussions with any other individual. The award document signed by the Grants Officer is the official authorizing document.

Federal Government Organizations: Funding made to federal government organizations (to include intramural DOD organizations) will be executed through the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

II.F.1.a. PI Changes and Award Transfers

Changes in PI are not allowed, except under extenuating circumstances that will be evaluated on a case-by-case basis and at the discretion of the Grants Officer. An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

The organizational transfer of an award supporting a clinical trial is strongly discouraged and in most cases will not be allowed.

An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 2, Section B, for general information on organization or PI changes.

II.F.2. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

Refer to the General Application Instructions, Appendix 2, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 5, for general information regarding national policy requirements.

Refer to full text of the latest <u>DoD R&D General Terms and Conditions</u>; the <u>USAMRAA</u> <u>General Research Terms and Conditions with Institutions of Higher Education, Hospitals, and</u> <u>Non-Profit Organizations: Addendum to the DoD R&D General Terms and Conditions</u>; and the <u>USAMRAA General Research Terms and Conditions with For-Profit Organizations</u> for further information.

II.F.3. Reporting

Refer to the General Application Instructions, Appendix 2, Section A, for general information on reporting requirements. *If there are technical reporting requirement delinquencies for any existing USAMRAA-sponsored awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.*

Annual progress reports as well as a final progress report will be required.

The Award Terms and Conditions will specify if more frequent reporting is required.

Award Expiration Transition Plan: An Award Expiration Transition Plan must be submitted with the final progress report. Use the one-page template "Award Expiration Transition Plan," available on the eBRAP "Funding Opportunities & Forms" web page (<u>https://ebrap.org/eBRAP/public/Program.htm</u>) under the "Progress Report Formats" section. The Award Expiration Transition Plan must outline if and how the research supported by this award will progress and must include source(s) of funding, either known or pending.

Inclusion Enrollment Reporting Requirement: Enrollment on the basis of sex/gender, race, and/or ethnicity will be required with each annual and final technical report. The suggested Inclusion Enrollment Report format is available on the "Funding Opportunities & Forms" web page (<u>https://ebrap.org/eBRAP/public/Program.htm</u>) in eBRAP.

Awards resulting from this program announcement will incorporate additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant, and cooperative agreement awards with a cumulative total value greater than \$10M are required to provide information to FAPIIS about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a federal award. Recipients are required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Application Instructions, Appendix 5, Section B).

II.G. Federal Awarding Agency Contacts

II.G.1. CDMRP Help Desk

Questions related to program announcement content or submission requirements as well as questions related to the pre-application or intramural application submission through eBRAP should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

Phone: 301-682-5507

Email: <u>help@eBRAP.org</u>

II.G.2. Grants.gov Contact Center

Questions related to extramural application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 800-518-4726; International 1-606-545-5035

Email: <u>support@grants.gov</u>

Sign up on Grants.gov for "send me change notification emails" by following the link on the "Synopsis" page for the program announcement or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this program announcement should refer to the program name, the program announcement name, and the program announcement version code 604a. The program

announcement numeric version code will match the General Application Instructions version code 604.

II.H.2. Administrative Actions

After receipt of applications, the following administrative actions may occur:

II.H.2.a. Rejection

The following will result in administrative rejection of the application:

- Pre-application was not submitted.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- More than one application for the TVA is received from the same investigator as the PI. Only the first application received from the same investigator will be accepted; additional applications will be administratively rejected.

II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.

II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- An FY21 LRP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. *A list of the FY21 LRP Programmatic Panel members can be found at <u>https://cdmrp.army.mil/lrp/panels/panels21</u>.*
- The application fails to conform to this program announcement description.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the

preparation, research or other duties for submitted applications. For FY21, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (<u>https://cdmrp.army.mil/about/2tierRevProcess</u>). Applications that include names of personnel from either of these companies may be administratively withdrawn.

- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- Applications from extramural organizations, including non-DOD federal agencies, received through eBRAP may be withdrawn.
- Applications submitted by an intramural DOD organization may be withdrawn if the intramural organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to extramural collaborators.
- Submission of the same research project to different funding opportunities within the same program and fiscal year.
- Preliminary data are not included.
- The PI does not meet the eligibility criteria.
- **Partnering PI Option:** Failure to submit all associated (Initiating and Partnering PI) applications by the deadline.
- The application does not address the FY21 LRP TVA Focus Area identified in <u>Section</u> <u>II.A.1, LRP Focus Areas</u>.
- Animal research is proposed.
- Application fails to include at least one consumer advocate on the research team as required by this program announcement.

II.H.2.d. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.

II.H.2.e. Other Funding Opportunities

The LRP is committed to leverage efforts with other funding organizations and will inform applicants when such opportunities are available so that they may give permission to release their application information for funding consideration.

Application Components	Action	Initiating PI Completed	Partnering PI Completed
SF424 Research & Related Application for Federal Assistance (extramural submissions only)	Complete form as instructed		
Summary (Tab 1) and Application Contacts (Tab 2) (intramural submissions only)	Complete tabs as instructed		
Attachments	Project Narrative: Upload as Attachment 1 with file name "ProjectNarrative.pdf" Supporting Documentation: Upload as Attachment 2 with file name "Support.pdf" Technical Abstract: Upload as Attachment 3 with file name "TechAbs.pdf" Lay Abstract: Upload as Attachment 4 with file name "LayAbs.pdf" Statement of Work: Upload as Attachment 5 with file name "SOW.pdf" Impact Statement: Upload as Attachment 6 with file name "Impact.pdf" Representations (extramural submissions only): Upload as Attachment 7 with file name "RequiredReps.pdf" if applicable Suggested Collaborating DOD Military Facility Budget Format: Upload as Attachment 8 with file name "MFBudget.pdf" if applicable		
Research & Related Personal Data	Complete form as instructed		
Research & Related Senior/Key Person Profile (Expanded)	Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field		

II.H.3. Application Submission Checklist

Application Components	Action	Initiating PI Completed	Partnering PI Completed
Research & Related Budget (extramural submissions only)	Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field		
Budget (intramural submissions only)	Complete the Suggested DOD Military Budget Format, including justification		
Project/Performance Site Location(s) Form	Complete form as instructed		
Research & Related Subaward Budget Attachment(s) Form	Complete form as instructed		

APPENDIX 1: ACRONYM LIST

ACOS/R&D	Associate Chief of Staff for Research and Development
ACURO	Animal Care and Use Review Office
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
DHA	Defense Health Agency
DHP	Defense Health Program
DOD	Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DUNS	Data Universal Numbering System
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FAPIIS	Federal Awardee Performance and Integrity Information System
FDA	Food and Drug Administration
FY	Fiscal Year
HRPO	Human Research Protection Office
IDE	Investigational Device Exemption
IND	Investigational New Drug
IRB	Institutional Review Board
LOI	Letter of Intent
LRP	Lupus Research Program
Μ	Million
MIPR	Military Interdepartmental Purchase Request
NIH	National Institutes of Health
OASD(HA)	Office of the Assistant Secretary of Defense for Health Affairs
ORCID	Open Researcher and Contributor ID, Inc.
ORP	Office of Research Protections
PI	Principal Investigator
RDT&E	Research, Development, Test, and Evaluation
SAM	System for Award Management
SOW	Statement of Work
STEM	Science, Technology, Engineering, and/or Mathematics
TVA	Transformative Vision Award
UEI	Unique Entity Identifier
USAMRAA	U.S. Army Medical Research Acquisition Activity
USAMRDC	U.S. Army Medical Research and Development Command
USC	United States Code
VA	Department of Veterans Affairs